A Safety Study of 212Pb-Pentixather Radioligand Therapy

* ability to provide independent consent

* adequate bone marrow function (platelet count ≥ 100,000; hemoglobin of ≥ 10 g/dL; neutrophil count ≥ 1,500 cells/mm3)

* adequate kidney function (creatinine clearance of ≥ 50 mL/min using the Cockcroft-Gault equation

* adequate liver function (serum bilirubin ≤ 3x the upper limit of normal, AST ≤ 5x the upper limit of normal, and ALT ≤ 5x the upper limit of normal)

* failed initial therapy or declined further therapy known to confer benefit

* have at least one lesion ≥ 2 cm that is positive for CXCR4 as demonstrated by Lead-203 Pentixather SPECT/CT

* major surgery within 4 weeks of consent

* antoher investigational agent within 4 weeks of consent

* uncontrolled illness including, but not limited to, ongoing or active infection that would necessitate a delay in therapy or cause a hospital admission, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic cirrhosis or severe impairment, or psychiatric illness/social situations that would limit compliance with study requirements.

* prior solid organ transplant

* cytotoxic or antineoplastic therapy within 21 days of consent (42 days for nitrosoureas)

* antibody therapy within the 21 days of consent

* allogenic bone marrow or stem cell transplant, or any stem cell infusion, within 84 days of consent

* pregnancy

* breastfeeding

* refusal to comply with birth control requirements during study